Determining LIMS Functionality, Cost, and ROI: System Architecture Strengths and Limitations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Determining LIMS Functionality, Cost, and ROI: System Architecture Strengths and Limitations
Before any information technology solution can be installed, a company must decide whether applications are going to reside on individual computers at each employee's workstation, on servers within or outside of an organization, or on a vendor's website.


Pharmaceutical Technology



Figure 1
Thick-client is used to describe an application designed to run in a client–server environment, meaning that a portion of the software resides on the server, and the other portion resides on the user's workstation. "Clients" are essentially the PCs or workstations. Also known as a fat client, it is a client that performs the bulk of any data-processing operation and relies on its associated server primarily for data storage. A thick-client has the LIMS installed on the PC's hard drive. The thick-client connects to the database server, but the processing is done on the client side (See Figure 1). Each change to the configuration or the application must take place at the client level; that is, the modifications must be propagated to each individual workstation. To provide the interconnectivity of each of the end-user locations, thick-client LIMS rely on cross platform programs such as Citrix.


Figure 2
Web-enabled is used to describe the add-on web browser component of an application designed to run in a client/server environment. The web-enabled portion of the application may allow access to data from a web browser, but the user is limited to the product functionality that is available on the web portion of the system (see Figure 2). To access and exploit the full functionality of the application, users must have the local client installed on their desktops. To provide the interconnectivity of each of these end-user locations, the web-enabled LIMS must also rely on cross-platform programs such as Citrix. Similarly, modifications must be propagated to each thick-client.


A laboratory information management systems comparison
Thin-client or web-based applications offer end-users full application functionality from a browser. A thin-client does not have significant hard drive or memory requirements, as it does not store or process data. The LIMS resides on the application server(s) while the thin-client simply presents the screen display and allows users to interact with the application server via a keyboard and a mouse. Configuration changes or customizations made on the server to the software are immediately universally available to all end-users. There is no need to propagate the changes to the end-user client or leverage regional servers with cross-platform programs.


Figure 3
The distinction between web-based and thin-client solutions is the amount of software residing on the client. A true thin-client LIMS is an application written specifically to run on the web, with zero-footprint on the end-user client. It only requires a browser or "dumb" client terminal to run the application residing on the server. No downloads, applets, or other programs exist on the end-user client, other than the browser (see Figure 3).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here